Seagen Inc. Announces New Data For ADCETRIS With Immunotherapy Combination In Hodgkin Lymphoma To Be Featured At 2023 ASH Annual Meeting, And Seagen To Unveil Novel CD30-Directed Antibody-Drug Conjugate
Portfolio Pulse from Benzinga Newsdesk
Seagen Inc. (NASDAQ:SGEN) announced that it will present new data for its drug ADCETRIS in combination with immunotherapy for Hodgkin lymphoma at the 2023 ASH Annual Meeting. The company will also unveil a novel CD30-directed antibody-drug conjugate, SGN-35C. The data will include 12- and 24-month progression free survival data for ADCETRIS and immunotherapy combination in early and advanced stage classical Hodgkin lymphoma. ADCETRIS is a proven foundation of care for certain CD30-expressing lymphomas with more than 120,000 patients treated globally across seven indications.
November 02, 2023 | 5:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Seagen's announcement of new data for ADCETRIS and the unveiling of SGN-35C could potentially boost investor confidence in the company's research and development capabilities. This could have a positive impact on the company's stock in the short term.
The announcement of new data for a proven drug and the unveiling of a novel drug candidate indicates progress in Seagen's research and development efforts. This could be seen as a positive signal by investors, potentially leading to increased demand for the company's stock.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100